AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Roche Reports 17% Jump in Net Income for First Half of 2025
ByAinvest
Thursday, Jul 24, 2025 5:51 am ET1min read
Swiss pharmaceutical giant Roche reported a 17% increase in net income to 7.8 billion Swiss francs ($9.85 billion) in the first half of 2025, driven by strong sales of asthma and breast cancer treatments. Sales exceeded forecasts, rising 4% to 30.9 billion Swiss francs. The company confirmed its full-year outlook and advanced four potentially "practice-changing" drugs into the final stage of clinical development.
Swiss pharmaceutical giant Roche reported a 17% increase in net income to 7.8 billion Swiss francs ($9.85 billion) in the first half of 2025, driven by strong sales of asthma and breast cancer treatments. Sales exceeded forecasts, rising 4% to 30.9 billion Swiss francs. The company confirmed its full-year outlook and advanced four potentially "practice-changing" drugs into the final stage of clinical development.Roche's Pharmaceuticals Division sales rose by 10% (6% in CHF), with key drivers including Phesgo (breast cancer), Xolair (food allergies), Hemlibra (haemophilia A), Vabysmo (severe eye diseases), and Ocrevus (multiple sclerosis) [1]. The Diagnostics Division sales were stable (-3% in CHF), as demand for pathology solutions and blood screening tests offset healthcare pricing reforms in China [1].
Core operating profit increased by 11% (6% in CHF) to 12.0 billion Swiss francs, driven by higher sales and effective cost management. Core earnings per share showed significant growth of 12% (8% in CHF) [1].
The company also announced several key approvals and positive data for various therapies, including Itovebi for advanced breast cancer, Evrysdi tablet for spinal muscular atrophy, and Susvimo for diabetic retinopathy [1]. Roche's CEO, Thomas Schinecker, noted the company's strong growth momentum and resilience, driven by its innovative on-market portfolio and pipeline.
The appreciation of the Swiss franc against most currencies had an adverse impact on results when reported in Swiss francs compared to constant exchange rates. However, the company expects an increase in Group sales in the mid single-digit range (CER) for 2025, with core earnings per share targeted to develop in the high single-digit range (CER). Roche also expects to further increase its dividend in Swiss francs [1].
References:
[1] https://www.roche.com/media/releases/med-cor-2025-07-24
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet